OncoMatch/Clinical Trials/NCT06918834
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Is NCT06918834 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for myelodysplastic syndromes.
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Lab requirements
Kidney function
Estimated glomerular filtration rate (eGFR) <50 mL/min [excluded]
Liver function
Serum bilirubin >1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT >5x upper limit of normal [excluded]
Cardiac function
Left ventricular ejection fraction <50% [excluded]
Severe organ dysfunction: Left ventricular ejection fraction <50%. Oxygen supplementation requirement. Serum bilirubin >1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT >5x upper limit of normal. Estimated glomerular filtration rate (eGFR) <50 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify